Principles-Of-Autonomic-Medicine-V
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Neurotransmitter Resource Guide
NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................ -
Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? Cheryl Lynn Smith
Claremont Colleges Scholarship @ Claremont CMC Senior Theses CMC Student Scholarship 2018 Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? Cheryl Lynn Smith Recommended Citation Smith, Cheryl Lynn, "Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions?" (2018). CMC Senior Theses. 1978. http://scholarship.claremont.edu/cmc_theses/1978 This Open Access Senior Thesis is brought to you by Scholarship@Claremont. It has been accepted for inclusion in this collection by an authorized administrator. For more information, please contact [email protected]. Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? A Thesis Presented by Cheryl Lynn Smith To the Keck Science Department Of Claremont McKenna, Pitzer, and Scripps Colleges In partial fulfillment of The degree of Bachelor of Arts Senior Thesis in Human Biology 04/23/2018 LIFETIME PREVALENCE AND PROGNOSIS OF SCHIZOPHRENIA 1 Table of Contents Abstract …………………………………………………………...……………………… 2 1. Introduction………………………………………………...…………...……………… 3 2. Background Information ……………………………...……………………………….. 5 2.1 Historical Background of Schizophrenia ……………………....…………… 5 2.2 Lifetime Prevalence of Schizophrenia …………………………...…..……… 12 2.3 Prognosis in People with Schizophrenia ……………....………...…..……… 13 3. Methods …………………………………………...……………………..……………. 17 4. Results ……………………………………………...…………………….…….…….... 18 5. Discussion ……………………………………………...……………………………… 24 6. Acknowledgements …………………………………………...………………………. -
Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder. -
ICD-10-CM TABULAR LIST of DISEASES and INJURIES 2018 Addenda No Change Chapter 1 No Change Certain Infectious and Parasitic Diseases (A00-B99)
ICD-10-CM TABULAR LIST of DISEASES and INJURIES 2018 Addenda No Change Chapter 1 No Change Certain infectious and parasitic diseases (A00-B99) No Change Intestinal infectious diseases (A00-A09) No Change A04 Other bacterial intestinal infections No Change A04.7 Enterocolitis due to Clostridium difficile Add A04.71 Enterocolitis due to Clostridium difficile, recurrent Add A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent No Change A05 Other bacterial foodborne intoxications, not elsewhere classified No Change Excludes1: Revise from Clostridium difficile foodborne intoxication and infection (A04.7) Revise to Clostridium difficile foodborne intoxication and infection (A04.7-) No Change Helminthiases (B65-B83) No Change B81 Other intestinal helminthiases, not elsewhere classified No Change Excludes1: Revise from angiostrongyliasis due to Parastrongylus cantonensis (B83.2) Revise to angiostrongyliasis due to: Add Angiostrongylus cantonensis (B83.2) Add Parastrongylus cantonensis (B83.2) No Change B81.3 Intestinal angiostrongyliasis Revise from Angiostrongyliasis due to Parastrongylus costaricensis Revise to Angiostrongyliasis due to: Add Angiostrongylus costaricensis Add Parastrongylus costaricensis No Change Chapter 2 No Change Neoplasms (C00-D49) No Change Malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-C80) No Change C79 Secondary malignant neoplasm of other and unspecified sites Delete Excludes2: lymph node metastases (C77.0) No Change C79.1 Secondary malignant neoplasm of bladder -
Physiological Studies of the Vestibulosympathetic Reflex in Humans
! ! ! Physiological Studies of the Vestibulosympathetic Reflex in Humans Elie Hammam, BMedSci (Hons I) School of Medicine University of Western Sydney Supervisor Prof. Vaughan Macefield Co-Supervisor Prof. Kenny Kwok A thesis submitted to the University of Western Sydney in candidature for the award of Doctor of Philosophy, 2014 ! ! "! ! ! ! STATEMENT OF AUTHENTICATION I, Elie Hammam, declare that this thesis is based entirely on my own independent work, except for sections which were performed in collaboration with colleagues as acknowledged in the study and resulted in the publication of the journal articles shown below. To the best of my knowledge this project does not contain material previously submitted in fulfillment of the guidelines and requirements for the award of Doctor of Philosophy in the School of Medicine, University of Western Sydney, and has not been submitted for qualifications at any other academic institution. Elie Hammam ! ! ! ! #! ! ! ! ACKNOWLEDGEMENTS Undertaking the highest scholarly exercise a University offers has certainly been a long, arduous, but nevertheless a fulfilling journey. Now completed, reflection has allowed me to appreciate that what I have achieved is merely a credit to my efforts. I am deeply indebted to the guidance of my mentors, encouragements from friends and support from family. First and foremost, I wish to acknowledge my stellar supervisor Vaughan Macefield who has never shied from supporting me throughout my candidature. Vaughan, from the very beginning you believed in me and never ceased to impart your knowledge, skills and wisdom. You have ensured all throughout my candidature that I get a holistic development in preparation to a life with academic excellence. -
A Sign It's Time for BOTOX®
When OAB* due to MS† makes matters worse… A sign it’s time for BOTOX® Ask your patients if they still have leakage or can’t tolerate their current OAB medication *Overactive bladder. †Multiple sclerosis. Indication Detrusor Overactivity Associated With a Neurologic Condition BOTOX® for injection is indicated for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, SCI, MS) in adults who have an inadequate response to or are intolerant of an anticholinergic medication. IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of BOTOX® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat Cervical Dystonia -
Autonomic Dysreflexia – a Medical Emergency a Guide for Patients
Autonomic Dysreflexia – A Medical Emergency A guide for patients Only applicable to T6 level and above Key Points • Autonomic Dysreflexia (AD) is a medical emergency that occurs due to a rapid rise in blood pressure in response to a harmful or painful stimulus below the level of your Spinal Cord Injury (SCI) • It occurs in people with SCI at T6 and above but has in rare occasions been reported in individuals with SCI as low as T8 • If left untreated your blood pressure can rise to dangerous levels, risking stroke, cardiac problems, seizures, even death • Typically there is a pounding headache as your blood pressure rises. Other symptoms can include redness and sweating above the level of your SCI, slow heart rate, goosebumps, nausea, nasal congestion, blurred vision, shortness of breath and anxiety • Some or all of the symptoms may be present • AD can be triggered by any continuous painful or irritating stimulus below the level of your lesion. The most common causes are related to the bladder or bowel • Relieving the cause of the AD will resolve your AD episode • If the cause cannot be found or treated, medication is required to lower your blood pressure which may require a visit to your nearest emergency department • All people with SCI at T6 and above should carry their Autonomic Dysreflexia Medical Emergency Card at all times • The best treatment for AD is prevention • People at risk of AD often carry an ‘AD Kit’ with them – items useful to resolve AD such as catheters and prescribed medication 1 What is Autonomic Dysreflexia? Autonomic Dysreflexia (AD) is a medical emergency. -
Treatment of Autonomic Dysreflexia for Adults & Adolescents with Spinal
Treatment of Autonomic Dysreflexia for Adults & Adolescents with Spinal Cord Injuries Authors: Dr James Middleton, Director, State Spinal Cord Injury Service, NSW Agency for Clinical Innovation. Dr Kumaran Ramakrishnan, Honorary Fellow, Rehabilitation Studies Unit, Sydney Medical School Northern, The University of Sydney, and Consultant Rehabilitation Physician & Senior Lecturer, Department of Rehabilitation Medicine, University Malaya. Dr Ian Cameron, Head of the Rehabilitation Studies Unit, Sydney Medical School Northern, The University of Sydney. Reviewed and updated in 2013 by the authors. AGENCY FOR CLINICAL INNOVATION Level 4, Sage Building 67 Albert Avenue Chatswood NSW 2067 PO Box 699 Chatswood NSW 2057 T +61 2 9464 4666 | F +61 2 9464 4728 E [email protected] | www.aci.health.nsw.gov.au Produced by the NSW State Spinal Cord Injury Service. SHPN: (ACI) 140038 ISBN: 978-1-74187-972-8 Further copies of this publication can be obtained from the Agency for Clinical Innovation website at: www.aci.health.nsw.gov.au Disclaimer: Content within this publication was accurate at the time of publication. This work is copyright. It may be reproduced in whole or part for study or training purposes subject to the inclusion of an acknowledgment of the source. It may not be reproduced for commercial usage or sale. Reproduction for purposes other than those indicated above, requires written permission from the Agency for Clinical Innovation. © Agency for Clinical Innovation 2014 Published: February 2014 HS13-136 ACKNOWLEDGEMENTS This document was originally published as a fact sheet for the Rural Spinal Cord Injury Project (RSCIP), a pilot healthcare program for people with a spinal cord injury (SCI) conducted within New South Wales involving the collaboration of Prince Henry & Prince of Wales Hospitals, Royal North Shore Hospital, Royal Rehabilitation Centre Sydney, Spinal Cord Injuries Australia and the Paraplegic & Quadriplegic Association of NSW. -
Assessment of Traumatic Nerve Injuries
American Association of Neuromuscular & Electrodiagnostic Medicine AANEM ASSESSMENT OF TRAUMATIC NERVE INJURIES Lawrence R. Robinson, MD Jeffrey G. Jarvik, MD, MPH David G. Kline, MD 2005 AANEM COURSE G AANEM 52nd Annual Scientific Meeting Monterey, California Assessment of Traumatic Nerve Injuries Lawrence R. Robinson, MD Jeffrey G. Jarvik, MD, MPH David G. Kline, MD 2005 COURSE G AANEM 52nd Annual Scientific Meeting Monterey, California AANEM Copyright © September 2005 American Association of Neuromuscular & Electrodiagnostic Medicine 421 First Avenue SW, Suite 300 East Rochester, MN 55902 PRINTED BY JOHNSON PRINTING COMPANY, INC. ii Assessment of Traumatic Nerve Injuries Faculty Lawrence R. Robinson, MD David G. Kline, MD Professor Boyd Professor and Head Department of Rehabilitation Medicine Department of Neurosurgery University of Washington Louisiana State University Medical Center Seattle, Washington New Orleans, Louisiana Dr. Robinson attended Baylor College of Medicine and completed his res- Dr. Kline is currently a Boyd Professor and Head of the Department of idency training in rehabilitation medicine at the Rehabilitation Institute of Neurosurgery at Louisiana State University (LSU) Medical Center in New Chicago. He now serves as professor and chair of the Department of Orleans. He earned his medical degree from the University of Rehabilitation Medicine at the University of Washington and is the Pennsylvania, then performed his internship at the University of Michigan. Director of the Harborview Medical Center Electrodiagnostic Laboratory. He performed residencies at the University of Michigan and Walter Reed He is also currently Vice Dean for Clinical Affairs at the University of General Hospital and Institute of Research. Dr. Kline has served on sever- Washington. -
Diagnostic Clues in Multiple System Atrophy
DO I:10.4274/Tnd.82905 Case Report / Olgu Sunumu Diagnostic Clues in Multiple System Atrophy: A Case Report and Literature Review Multisistem Atrofi Tanısında İpuçları: Bir Olgu Sunumu ve Literatürün Gözden Geçirilmesi Mehmet Yücel, Oğuzhan Öz, Hakan Akgün, Semai Bek, Tayfun Kaşıkçı, İlter Uysal, Yaşar Kütükçü, Zeki Odabaşı Gülhane Military Medical Academy, Ankara, Turkey Sum mary Multiple system atrophy (MSA) is an adult-onset, sporadic, progressive neurodegenerative disease. Based on the consensus criteria, patients with MSA are clinically classified into cerebellar (MSA-C) and parkinsonian (MSA-P) subtypes. In addition to major diagnostic criteria including poor response to levodopa, and presence of pyramidal or cerebellar signs (ataxia) or autonomic failure, certain clinical features or ‘‘red flags’’ may raise the clinical suspicion for MSA. In our case report we present a 67-year-old female patient admitted to our hospital due to inability to walk, with poor response to levodopa therapy, whose neurological examination revealed severe Parkinsonism, ataxia and who fulfilled all criteria for MSA, as rarely seen in clinical practice.(Turkish Journal of Neurology 2013; 19:28-30) Key Words: Multiple system atrophy, autonomic failure, diagnostic criteria Özet Multisistem atrofi (MSA) erişkin dönemde başlayan, ilerleyici, nedeni bilinmeyen sporadik nörodejeneratif bir hastalıktır. MSA kabul görmüş tanı kriterlerine göre klinik olarak serebellar (MSA-C) ve parkinsoniyen (MSA-P) alt tiplerine ayrılmaktadır. Düşük levadopa yanıtı, piramidal, serebellar bulguların (ataksi) ya da otonomik bozukluk olması gibi majör tanı kriterlerininin yanında “red flags” olarak isimlendirilen belirgin klinik bulgular ya da uyarı işaretlerinin olması MSA tanısı için klinik şüpheyi oluşturmalıdır. Olgu sunumunda 67 yaşında yürüyememe şikayeti ile polikliniğimize müracaat eden ve levadopa tedavisine düşük yanıt gösteren ciddi parkinsonizm bulguları ile ataksi bulunan kadın hasta MSA tanı kriterlerini tam olarak karşıladığı ve klinik pratikte nadir görüldüğü için sunduk. -
Xerox University Microfilms
INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1.The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page{s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You will find a good image of the page in the adjacent frame. 3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete. 4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation. -
Pheochromocytoma: a Single-Center Retrospective Review
Central Journal of Clinical Nephrology and Research Review Article *Corresponding author Jose Rueda, MD, Division of Nephrology and Hypertension, Oregon Health & Science University, Mail Code: SJH6, 3181 S.W. Sam Jackson Park Road, Pheochromocytoma: A Single- Portland, OR 97239-309, Tel: 5034943442; Email: [email protected] Submitted: 18 February, 2021 Center Retrospective Review Accepted: 22 February, 2021 Benjamin K Elstrott1*, Lubna Khan2*, Divine Ribakare1,2, Published: 24 February, 2021 ISSN: 2379-0652 Abdallah Alali1,2, Ali Olyaei1,2,4, James Y Lim1,3, Jose F Rueda1,2 Copyright 1 Oregon Health & Science University, Portland © 2021 Elstrott BK, et al. 2Division of Nephrology and Hypertension, Portland OPEN ACCESS 3Department of Surgery, Portland 4Oregon State University, College of Pharmacy Keywords • Pheochromocytoma Abstract • Adrenal Gland Neoplasms • Incidental Findings Background: The presentation of modern pheochromocytoma is changing alongside advances in • Adrenal medulla medical practice. This retrospective review depicts the clinical presentation and biochemical properties of • Adrenalectomy pheochromocytomas as a function of size and cause for workup. Materials and Methods: Single-center retrospective chart review of imaging studies, biochemical testing results, and provider documentation written prior to surgical resections performed for pheochromocytoma between 1998 and 2018. Results: Forty-four patients were found to have 49 pheochromocytomas on pathology. The most common presentation was through incidental imaging findings of an adrenal mass (38.6%), followed by symptoms (34.1%), and then screening for known genetic risk (27.3%). Median unenhanced CT attenuation was 36 HU (range 17-85). Median pheochromocytoma size on imaging was 3.4 cm (range 1.0-12.2 cm). Median mass size in symptoms, incidental mass, and genetic risk groups were 4.1 cm, 3.4 cm, and 2.3 cm respectively (p = 0.090).